Brochure
In Vitro Pharmacology Solutions
In Vitro Pharmacology
Solutions
Acquiring a holistic grasp of your molecules
Highlight of In Vitro Pharmacology Platform
> 97%
delivery
rate
30+ CMC-integrated projects
100+ IND supporting projects
IND-compliance report
Certificate of 3Q and CSV
Certified BSL-2 labs
100%
pass rate
for IND
1400+
delivered
projects
project
Highlights
6
Biologics and vaccine
CGT evaluation
Comprehensive primary
cell assays
1000+
proprietary
cell lines
300+ reporter cells
(part of which were pre-qualified)
450+ overexpression cell lines
functional
platforms
(21+ fields)
16-year
experience
in platforms
Assay Platform
Absorbance-based assays
Luminescence-based assays
Fluorescence-based assays
High content analysis
Live cell imaging system
Flow cytometry & cell sorting
GPCR screening assays
CAR functional analysis
Reporter gene assays
Primary cell-based assays
HTRF-based assays
Virus infection assays
Bioactivity of monoclonal Ab
Aspects for monoclonal Ab evaluation
Fab domain
Fc domain
MOA: Fc mediates effects
MOA: Fab binds to target protein
to exert effects
Bioactivity analysis of Fab domain
Bioactivity analysis of Fc domain
Functional assays
Antibody-dependent cellular cytotoxicity (ADCC)
assays
Antibody-dependent cellular phagocytosis (ADCP)
assays
Complement-dependent cytotoxicity assay (CDC)
assays
Functional assays
Binding assays
Agonist activity
Ligand blockade activity
Neutralization assays
Preclinical safety assessment
Cytokine release syndrome assessment
Species cross reactivity assessment
Preclinical safety assessment
Antibody-dependent enhancement(ADE) test
Induction of cytotoxicity in non-targeted cells
More customized assays
1
Bispecific Ab characterization
Aspects for BsAb evaluation
Fab Region
Fab Region
MOA: Fab region binds to target
MOA: Fab region binds to target
antigen
antigen
Dual target blockade/
In cis cell surface
In trans cell bridging assay
T cell engager
modulatory assay
protein bridging assay
Blocking angiogenesis and/or
tumorigenesis
Apoptotic signaling pathway
Coagulation pathway
NK cell engager
Modulating tumor microenvironment
(TME)
Anti-TAA x co-stimulatory
immune checkpoint
Targeting inflammatory/autoimmune
diseases
Anti-TAA x co-inhibitory
immune checkpoint
Blocking angiogenesis and/or
tumorigenesis x Anti-immune
checkpoint
ADC characterization
Aspects for ADC evaluation
Fab Region
Payload
MOA: Fab region binds to target
antigen, triggering endocytosis
Cell based assay: antibody
internalization assay
MOA: a cell-killing cytotoxic drug
conjugated in Ab, inducing target
cell death
Cell based assay: cytotoxicity assay
Antibody internalization assay
Cytotoxicity assay
By-stander effect
Antigen-mediated internalization is a
critical characteristic of ADC
candidates.
Cytotoxicity assays,
Bystander cell is the surround-
ing cell of tumor, which could
be Ag+ or Ag-. When the tumor
cell is lysed, the uptaken toxin
will be released to kill neighbor-
ing cells.
measuring the killing
potential of ADCs are a
necessary first step to triage
CellTiter-Glo®
CCK8
Live-cell imaging based internalization
pH-indicator based internalization
Toxin-conjugated mAb based
cytotoxicity assay DT3C/VHH-DT
/FabFc-ZAP
Medium transfer or co-culture
assay using live cell imaging or
Flow cytometry
LDH
Luminescence/fluores-
cence-based
Temperature shift based internalization
2
Scope
Internalization assay
Live-cell imaging
based
internalization
Temperature shift
based
internalization
Cell based
assay
Toxin-conjugated mAb based
cytotoxicity assay
pH-indicator based
internalization
General
Temperature
Shift
Incucyte
DT3C
FabFc-ZAP
pHrodo
designation
Live-Cell Analyzer
Incucyte®
Diagram
Herceptin-Fabfluor
Naked Antibody
Microplate Reader
Molecule
Analyzer
Live-Cell Analyzer
FACS
FACS
High sensitivity
High throughput
Close to the cytotoxic MOA
Cost-effective
Susceptible
to multiple factors
Real-time and
kinetics analysis
High sensitivity
Low throughput
Feature
Most versatile
Best choice
Alternative choice
Optional
Optional
Optional
Application
Case study
Cell line engineering for assays
High quality of cell line development
Substantial cell library: 300+ in-house reporter cell lines; 450+ overexpression cell lines
Clear tracebility and construction records, ensuring the compliance with ICH and FDA guidelines
Efficient method development process: meets the requirements throughout both of the ADD and
CMC stages, with a 100% success rate in method qualification. Cases for lot release (ADCC, PD-1, 4-1BB,
PVRIG, VEGF etc.)
Work-flow of bioassay cell line development
Clone
Screening
and Selection
Vector Design
and
Construction
Comprenhensive
Characterization
(optional)
Evaluation
of Assay
Cell Line
Expansion
for Bioassay
(optional)
Cell
Transfection
Validation of
Cell Pool
1 week
2-3 weeks
2-4 weeks
1-2 weeks
4-6 weeks
12-15 weeks
2-4 weeks
3
Part of popular assay cell line list developed at ProBio
Category
Cat. No. Target
Product
Category Cat. No. Target Product
ADCC
RD00830 CD16a 158V
RD00941 CD32/CD64
RD00901 4-1BB
GS-J2C/CD16a 158V
ADCP reporter
TCE
TRD00812 CD3
GS-J2C
ADCP
Cytokine RD01027
Cytokine RD01026
Cytokine RD00956
Cytokine RD00934
Cytokine RD00932
Cytokine RD00930
Cytokine RD00908
Cytokine RD00869
Cytokine RD00704
IL-22
IL-21
IL-22 Reporter cell
GS-U2/IL-21R
GS-H3/RANK
GS-E9/IL-12R
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
Immune checkpoint
GS-H3/4-1BB
RD00718
CD40
GS-H3/CD40
RANK
IL-12R
RD00940 LAG3
RD01036 BTLA
RD01034 Trem2
RD01005 KIR3DL3
RD00841 PVRIG
GS-J4B/LAG3
GS-J2B/BTLA
IL-23R GS-E8/IL-23R
GHR GS-E7/GHR
TSLPR GS-E6/IL-7Ra/TSLPR
GS-J2C/DAP12/Trem2
GS-J4B/KIR3DL3
GS-J2C/PVRIG
EPOR
VEGF
GS-E6/EPOR
M00695
TIGIT/PD-1
GS-J2/TIGIT/PD-1
GS-J2B/PD-1/BTLA
GS-J4B/CTLA4/PD-1
GS-J7/4-1BB/PD-1
GS-E3/VEGFR2
RD01038 BTLA/PD-1
RD00942 CTLA4/PD-1
RD00899 4-1BB/PD-1
GPCR
GPCR
GPCR
RD01035
RD00938
RD00918
GCGR CHO-K1/CRE-Luc/GCGR
GIPR HEK293/CRE-Luc/GIPR
GLP-1R CHO-K1/CRE-Luc/GLP-1R
Research grade virus packaging and testing platform
One-stop solution: end-to-end services, including gene synthesis, virus packaging, and functional
evaluation, all tailored to your gene of interest.
Lentivirus
Retrovirus
AAV/AdV
Customized virus
Pipeline of virus packaging and functional analysis
Proposal
design
Plasmid
Virus/vector
packaging
Virus/vector
In vitro functional
analysis
preparation
purification (optional)
2-4 weeks
1 week
1 week
1-2 weeks
CGT product functional characterization - CAR-T/NK in vitro
assay service
Comprehensive CAR-T/NK in vitro pharmacology platform offering a range of services to support
clients in developing CAR cell therapy
Highlights:
High-throughput screening: high throughput and cost-effective platform for CAR lead screening
Experience and expertise: versatile in vitro bioassays to validate CAR-T/NK cell function, backed
by our extensive experience and expertise
Work-flow
Generation of CAR
encoding vector
T/NK cell activation
and transduction
Expansion of
CAR-T/NK cells
Functional assay for cytotoxicity
and cytokine release
FTO CAR vector
Non-virus transfection
Lentivirus
High fold expansion
Time-based killing assay
Cancer cell lines
Retrovirus
Overexpression cell lines
Luciferase target cells
GPCR drug screening and evaluation
57 families covering 153 GPCR targets and providing HTS screening assays
> 200 GPCR functional assays
4
3
assay types (cAMP, calcium flux, beta-Arrestin and binding), covering almost GPCR signaling pathways
analysis of pharmacological MoAs (Agonist, Antagonist, Allosteric modulation)
4
ProBio Inc.
Building 9, 311 Pennington Rocky Hill Rd,
Pennington, NJ